Matinas Biopharma Holdings Inc (AMEX:MTNB) currently has a daily average trading volume of 1.55M but it saw 879335 shares traded in last market. With a market cap of 52.42M USD, the company’s current market price of $0.21 came falling about -1.83 while comparing to the previous closing price of $0.21. In past 52 weeks, the stock remained buoying in the range of price level as high as $0.89 and as low as $0.11.
Taking a look at 20-day trading activity of Matinas Biopharma Holdings Inc (MTNB) gives us an average price of $0.2664, while its current price level is -76.52% below from 52-week high level whereas it is 89.48% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.2490 while that of 200 days or SMA-200 reads an average of $0.2399. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.41% during that period while stretching the period over a month that increases to 14.97%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 40.88 which implies that the stock is in neutral territory.
Piper Sandler issued its recommendations for the stock as it initiated the price target for the stock is $3.
Over the week, MTNB’s stock price is moving -8.13% down while it is -22.88% when we observe its performance for the past one month. Year-to-date it is -3.33% down and over the past year, the stock is showing a downside performance of -50.95%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of -$0.02 beat the consensus estimate of -$0.03 for the same. For MTNB, analysts are forecasting an EPS-growth rate of -9.10% for current year and estimate for EPS growth in next year is 16.70%.
Currently, Matinas Biopharma Holdings Inc’s total number of outstanding shares is 250.82M with 2.91% of that held by the insiders while 12.05% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -103.62% and return on equity (ROE) at -82.11%. Stock’s beta reads 1.58. Stock has a price to book (P/B) ratio of 2.36 while price to sale or P/S ratio amounts to 47.66. Its return on asset (ROA) is -31.77% on average.
